In a report released yesterday, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Werewolf Therapeutics, with a price target of $10.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Werewolf Therapeutics’ promising advancements in their drug development pipeline. The company’s lead prodrug, WTX-124, is advancing in its clinical trials, with a significant interim data release expected in late 2025 for melanoma and renal cell carcinoma. This progress, coupled with the company’s plans to engage with the FDA for a potential registrational pathway, underscores growing confidence in their therapeutic approach.
Additionally, the development of WTX-330 and WTX-1011 further strengthens Werewolf’s position. WTX-330 is making strides in dose optimization, which is crucial for its scalability across various cytokine therapies. Meanwhile, WTX-1011’s innovative design targets prostate cancer with promising preclinical results. These advancements suggest that Werewolf’s platform can effectively address the limitations of traditional cytokine therapies, supporting the Buy rating and a price target of $10.
In another report released on August 4, Jefferies also initiated coverage with a Buy rating on the stock with a $4.00 price target.